You are here
Gold Standard Research & Evidence for Vaccines
Maura L. Gillison, Tatevik Broutian, Barry Graubard, Robert Pickard, Zhen-Yue Tong, Weihong Xiao, Lisa Kahle, Anil Chaturvedi; Ohio State University, Columbus, OH; National Cancer Institute, Rockville, MD; The Ohio State University, Columbus, OH; Informat. "Impact of HPV vaccination on oral HPV infections among young adults in the U.S.." Meeting Library, ASCO University, June 5, 2017.
The incidence of HPV-positive oropharyngeal cancers has risen in recent decades among US men. The potential impact of HPV vaccines on oral HPV infections has yet to be evaluated in efficacy-trials or surveillance studies.
HPV vaccination substantially reduced vaccine-type oral HPV infection prevalence among young adults (ages 18-33 years) in the US population during 2011-2014. However, due to low vaccine uptake, population-level effectiveness was modest overall and particularly low in men.
Elissa Meites, MD; Allison Kempe, MD; Lauri E. Markowitz, MD. "Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices." Centers for Disease Control and Prevention, December 16, 2016.
This report provides recommendations and guidance regarding use of HPV vaccines and updates ACIP HPV vaccination recommendations previously published in 2014 and 2015